Dear Patients and Their Families:
Hello, currently, Peking University First Hospital, Beijing Luhe Hospital, Beijing Chaoyang Hospital, Beijing Hospital, Xuanwu Hospital, Friendship Hospital, Xiyuan Hospital, and several other hospitals are conducting a “Phase III multicenter, randomized, double-blind, double-dummy, positive drug-controlled, parallel design clinical study to evaluate the efficacy and safety of HR091506 tablets in patients with gout accompanied by hyperuricemia.” HR091506 tablets are a sustained-release formulation of febuxostat, expected to improve the reduction of serum uric acid by prolonging the effective blood concentration duration of febuxostat, intended for the treatment of hyperuricemia in gout patients.
Recruitment Criteria:
- Age between 18 and 75 years old (inclusive), body mass index (BMI) between 18.0 and 30.0 kg/m² (inclusive), both male and female;
- History of gout diagnosis;
- Fasting serum uric acid levels ≥ 480 umol/L in two non-consecutive tests during the screening period;
- No acute gout attack in the past 4 weeks;
- No history of major diseases;
- No history of drug abuse, substance addiction, and/or excessive alcohol consumption;
- Excluding pregnant or lactating women or those with positive pregnancy tests;
- Willing to sign the informed consent form.
If you or your family members or friends meet the above requirements, please feel free to contact us. You will receive free treatment and examinations for the entire course.
Contact Person
Teacher Liang: 13253538415
Please note that you are contacting us through the Shitu website